RNA-interference (RNAi) Market Size, Share, Growth, Trends with Impact of Covid-19 and Forecast by 2022-2030

The report offers a latest study about the present worldwide market development strategy, pre and post covid-19 situation, by latest trends and drivers, and type, application. The report on RNA-interference (RNAi) market offers qualitative along with quantitative study in terms of market dynamics, competition scenarios, opportunity analysis, market growth, industrial chain, and forecast by 2021-2024.

RNA-interference (RNAi) Market Report is projected to grow at a CAGR of 20.2% during the forecast period 2021-2024.

Company Coverage: -
- Alnylam Pharmaceuticals
- Arcturus Therapeutics
- Arrowhead
- Dicerna Pharmaceuticals
- Ionis Pharmaceuticals Inc.
- Merck & Co. Inc. (Sigma Aldrich)
- Qiagen NV
- Thermo Fisher Scientific Inc.
- Quark Pharmaceuticals Inc.
- Silence Therapeutics PLC
- Phio Pharmaceuticals Corp.

Scope: -
RNA interference is a biological process in which the RNA molecules are observed to inhibit gene expression or translation, by neutralizing the targeted mRNA molecules. Earlier, RNAi was identified by other names, such as co-suppression, post-transcriptional gene silencing (PTGS), and quelling. The extensive study of each of these apparently different processes clarified that the identity of these phenomena were all in fact RNAi.

Regions: -

- North America

- Asia-Pacific

- Europe

- South America

- Africa


Key Highlights of Report:

- Provides market definition and overview by studying objectives like market scope and market size estimation.
- Provides research methods and logic based on historic data.
- Analysis market competition, market performance worldwide, manufactures basic information, Sales, Value, Price and Gross Margin.
- Analysis on segmentation of types, applications and regions based on historical Data and market forecasts.